391 related articles for article (PubMed ID: 30826768)
1. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
Nishimura R; Kato H; Kisanuki K; Oh A; Hiroi S; Onishi Y; Guelfucci F; Shimasaki Y
BMJ Open; 2019 Mar; 9(3):e025806. PubMed ID: 30826768
[TBL] [Abstract][Full Text] [Related]
2. Comparison of persistence and adherence between fixed-dose combinations and two-pill combinations in Japanese patients with type 2 diabetes.
Nishimura R; Kato H; Kisanuki K; Oh A; Onishi Y; Guelfucci F; Shimasaki Y
Curr Med Res Opin; 2019 May; 35(5):869-878. PubMed ID: 30460858
[TBL] [Abstract][Full Text] [Related]
3. Comparison of persistence and adherence between DPP-4 inhibitor administration frequencies in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
Oh A; Kisanuki K; Nishigaki N; Shimasaki Y; Sakaguchi K; Morimoto T
Curr Med Res Opin; 2020 Mar; 36(3):387-395. PubMed ID: 31778076
[No Abstract] [Full Text] [Related]
4. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan.
Wake M; Onishi Y; Guelfucci F; Oh A; Hiroi S; Shimasaki Y; Teramoto T
Atherosclerosis; 2018 May; 272():145-152. PubMed ID: 29604481
[TBL] [Abstract][Full Text] [Related]
6. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents in Japanese patients with type 2 diabetes mellitus: a claims database analysis.
Nishimura R; Takeshima T; Iwasaki K; Aoi S
BMJ Open; 2022 Mar; 12(3):e045966. PubMed ID: 35277396
[TBL] [Abstract][Full Text] [Related]
8. Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan.
Wake M; Oh A; Onishi Y; Guelfucci F; Shimasaki Y; Teramoto T
Atherosclerosis; 2019 Mar; 282():19-28. PubMed ID: 30669019
[TBL] [Abstract][Full Text] [Related]
9. Adherence to dipeptidyl peptidase-4 inhibitor therapy among type 2 diabetes patients with employer-sponsored health insurance in Japan.
Kurtyka K; Nishikino R; Ito C; Brodovicz K; Chen Y; Tunceli K
J Diabetes Investig; 2016 Sep; 7(5):737-43. PubMed ID: 27182033
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND).
Tajima A; Tobe K; Eiki JI; Origasa H; Watada H; Shimomura I; Tokita S; Kadowaki T
BMJ Open Diabetes Res Care; 2022 Dec; 10(6):. PubMed ID: 36585033
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
12. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis.
Kadowaki T; Sarai N; Hirakawa T; Taki K; Iwasaki K; Urushihara H
Diabetes Obes Metab; 2018 Dec; 20(12):2830-2839. PubMed ID: 29974673
[TBL] [Abstract][Full Text] [Related]
13. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
14. Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42).
Fujihara K; Igarashi R; Matsunaga S; Matsubayashi Y; Yamada T; Yokoyama H; Tanaka S; Shimano H; Maegawa H; Yamazaki K; Kawai K; Sone H
Medicine (Baltimore); 2017 Feb; 96(7):e6122. PubMed ID: 28207538
[TBL] [Abstract][Full Text] [Related]
15. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
Cai J; Divino V; Burudpakdee C
Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
17. Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012-2020: a Time-Series Analysis.
Iketani R; Imai S
Biol Pharm Bull; 2023; 46(4):592-598. PubMed ID: 37005303
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study.
Zerovnik S; Kos M; Locatelli I
BMJ Open; 2021 Sep; 11(9):e051549. PubMed ID: 34518273
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
Komamine M; Kajiyama K; Ishiguro C; Uyama Y
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
[TBL] [Abstract][Full Text] [Related]
20. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
